Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 112

1.

Association of platelet ITGA2B and ITGB3 polymorphisms with ex vivo antiplatelet effect of ticagrelor in healthy Chinese male subjects.

Li MP, Xiong Y, Xu A, Zhou JP, Tang J, Zhang ZL, Zhou HH, Zhang W, Chen XP.

Int J Hematol. 2014 Mar;99(3):263-71. doi: 10.1007/s12185-014-1502-5. Epub 2014 Jan 29.

PMID:
24474638
2.

Influence of P2Y12 polymorphisms on platelet activity but not ex-vivo antiplatelet effect of ticagrelor in healthy Chinese male subjects.

Li MP, Tang J, Wen ZP, Zhang YJ, Zhang W, Zhou HH, Zhang ZL, Chen XP.

Blood Coagul Fibrinolysis. 2015 Dec;26(8):874-81. doi: 10.1097/MBC.0000000000000308.

PMID:
26083990
3.

Identification of ITGA2B and ITGB3 Single-Nucleotide Polymorphisms and Their Influences on the Platelet Function.

Xiang Q, Ji SD, Zhang Z, Zhao X, Cui YM.

Biomed Res Int. 2016;2016:5675084. Epub 2016 Nov 14.

4.

Ticagrelor yields consistent dose-dependent inhibition of ADP-induced platelet aggregation in patients with atherosclerotic disease regardless of genotypic variations in P2RY12, P2RY1, and ITGB3.

Storey RF, Melissa Thornton S, Lawrance R, Husted S, Wickens M, Emanuelsson H, Cannon CP, Heptinstall S, Armstrong M.

Platelets. 2009 Aug;20(5):341-8. doi: 10.1080/09537100903075324.

PMID:
19637098
5.

Comparison of antiplatelet effects of prasugrel and ticagrelor in cynomolgus monkeys by an ELISA-based VASP phosphorylation assay and platelet aggregation.

Tomizawa A, Ohno K, Jakubowski JA, Mizuno M, Sugidachi A.

Thromb Haemost. 2013 Oct;110(4):769-76. doi: 10.1160/TH13-03-0260. Epub 2013 Aug 1.

PMID:
23903326
6.

Reversal strategy in antagonizing the P2Y12 -inhibitor ticagrelor.

Hobl EL, Derhaschnig U, Firbas C, Schoergenhofer C, Schwameis M, Jilma B.

Eur J Clin Invest. 2013 Dec;43(12):1258-61. doi: 10.1111/eci.12168. Epub 2013 Sep 23.

PMID:
24112116
7.

No Effect of SLCO1B1 and CYP3A4/5 Polymorphisms on the Pharmacokinetics and Pharmacodynamics of Ticagrelor in Healthy Chinese Male Subjects.

Li M, Hu Y, Li H, Wen Z, Hu X, Zhang D, Zhang Y, Xiao J, Tang J, Chen X.

Biol Pharm Bull. 2017;40(1):88-96. doi: 10.1248/bpb.b16-00686.

8.

Lack of association between aspirin responsiveness and seven candidate gene haplotypes in patients with symptomatic vascular disease.

Kunicki TJ, Williams SA, Nugent DJ, Harrison P, Segal HC, Syed A, Rothwell PM.

Thromb Haemost. 2009 Jan;101(1):123-33.

PMID:
19132198
9.

Adenosine diphosphate-induced platelet aggregation is associated with P2Y12 gene sequence variations in healthy subjects.

Fontana P, Dupont A, Gandrille S, Bachelot-Loza C, Reny JL, Aiach M, Gaussem P.

Circulation. 2003 Aug 26;108(8):989-95. Epub 2003 Aug 11.

10.

Effect of P2Y1 and P2Y12 genetic polymorphisms on the ADP-induced platelet aggregation in a Korean population.

Kim KA, Song WG, Lee HM, Joo HJ, Park JY.

Thromb Res. 2013 Aug;132(2):221-6. doi: 10.1016/j.thromres.2013.06.020. Epub 2013 Jul 10.

PMID:
23849096
11.

Pharmacokinetics, pharmacodynamics, safety and tolerability of multiple ascending doses of ticagrelor in healthy volunteers.

Butler K, Teng R.

Br J Clin Pharmacol. 2010 Jul;70(1):65-77. doi: 10.1111/j.1365-2125.2010.03669.x.

12.

Ticagrelor: the first reversibly binding oral P2Y12 receptor antagonist.

Husted S, van Giezen JJ.

Cardiovasc Ther. 2009 Winter;27(4):259-74. doi: 10.1111/j.1755-5922.2009.00096.x. Review.

13.

Third generation P2Y12 antagonists inhibit platelet aggregation more effectively than clopidogrel in a myocardial infarction registry.

Olivier CB, Diehl P, Schnabel K, Weik P, Zhou Q, Bode C, Moser M.

Thromb Haemost. 2014 Feb;111(2):266-72. doi: 10.1160/TH13-06-0508. Epub 2013 Oct 31.

PMID:
24172891
14.

Association of PEAR1 rs12041331 polymorphism and pharmacodynamics of ticagrelor in healthy Chinese volunteers.

Li M, Hu Y, Wen Z, Li H, Hu X, Zhang Y, Zhang Z, Xiao J, Tang J, Chen X.

Xenobiotica. 2017 Jan 12:1-9. doi: 10.1080/00498254.2016.1271962. [Epub ahead of print]

PMID:
27937053
15.

Pharmacokinetics and tolerability of single and multiple doses of ticagrelor in healthy Chinese subjects: an open-label, sequential, two-cohort, single-centre study.

Li H, Butler K, Yang L, Yang Z, Teng R.

Clin Drug Investig. 2012 Feb 1;32(2):87-97. doi: 10.2165/11595930-000000000-00000.

PMID:
22168538
16.

Effects of ex vivo platelet supplementation on platelet aggregability in blood samples from patients treated with acetylsalicylic acid, clopidogrel, or ticagrelor.

Hansson EC, Shams Hakimi C, Åström-Olsson K, Hesse C, Wallén H, Dellborg M, Albertsson P, Jeppsson A.

Br J Anaesth. 2014 Mar;112(3):570-5. doi: 10.1093/bja/aet339. Epub 2013 Oct 22.

PMID:
24148324
17.

High-dose aspirin in dogs increases vascular resistance with limited additional anti-platelet effect when combined with potent P2Y12 inhibition.

Björkman JA, Zachrisson H, Forsberg GB, von Bahr H, Hansson GI, Warner TD, Nylander S.

Thromb Res. 2013 Apr;131(4):313-9. doi: 10.1016/j.thromres.2013.01.029. Epub 2013 Feb 15.

PMID:
23419412
18.

Characterisation of patients with Glanzmann thrombasthenia and identification of 17 novel mutations.

Sandrock-Lang K, Oldenburg J, Wiegering V, Halimeh S, Santoso S, Kurnik K, Fischer L, Tsakiris DA, Sigl-Kraetzig M, Brand B, Bührlen M, Kraetzer K, Deeg N, Hund M, Busse E, Kahle A, Zieger B.

Thromb Haemost. 2015 Apr;113(4):782-91. doi: 10.1160/TH14-05-0479. Epub 2014 Nov 6.

PMID:
25373348
19.

Frequency of genetic polymorphisms of COX1, GPIIIa and P2Y1 in a Chinese population and association with attenuated response to aspirin.

Li Q, Chen BL, Ozdemir V, Ji W, Mao YM, Wang LC, Lei HP, Fan L, Zhang W, Liu J, Zhou HH.

Pharmacogenomics. 2007 Jun;8(6):577-86.

PMID:
17559347
20.

The effect of desmopressin on bleeding time and platelet aggregation in healthy volunteers administered ticagrelor.

Teng R, Mitchell PD, Butler K.

J Clin Pharm Ther. 2014 Apr;39(2):186-91. doi: 10.1111/jcpt.12130. Epub 2014 Jan 21.

PMID:
24444280

Supplemental Content

Support Center